安旭生物(688075) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 reached ¥5,474,543,757.08, representing a significant increase of 2,763.42% compared to the same period last year[5] - The net profit attributable to shareholders was ¥2,681,700,014.97, reflecting a growth of 3,147.87% year-over-year[5] - Basic earnings per share (EPS) stood at ¥43.77, marking an increase of 2,340.41% compared to the previous year[6] - Operating profit for Q1 2022 was ¥3,119,833,088.15, compared to ¥97,675,781.93 in Q1 2021, indicating a year-over-year increase of about 3,090%[23] - Net profit for Q1 2022 amounted to ¥2,681,700,014.97, a substantial rise from ¥82,567,996.10 in the same period last year, reflecting an increase of approximately 3,145%[23] - Basic and diluted earnings per share for Q1 2022 were both ¥43.77, compared to ¥1.79 in Q1 2021, marking an increase of about 2,440%[24] - Total operating costs for Q1 2022 were ¥2,329,561,768.93, up from ¥92,732,699.09 in Q1 2021, which is an increase of about 2,411%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,591,112,000.17, which is a 131.41% increase from the end of the previous year[6] - Total current assets as of March 31, 2022, amounted to ¥7,178,192,740.97, a significant increase from ¥2,979,405,144.48 as of December 31, 2021, indicating a growth of approximately 141%[16] - Total assets reached ¥7,591,112,000.17, compared to ¥3,280,443,711.10 at the end of 2021, marking a growth of around 131%[17] - Total liabilities increased to ¥2,296,071,679.32 from ¥673,946,234.90, which is an increase of approximately 241%[18] - The total equity attributable to shareholders of the parent company as of Q1 2022 was ¥5,295,040,320.85, compared to ¥2,606,497,476.20 in Q1 2021, representing an increase of approximately 103%[22] - Total liabilities and equity amounted to ¥7,591,112,000.17 in Q1 2022, compared to ¥3,280,443,711.10 in Q1 2021, indicating a growth of about 131%[22] Cash Flow - The net cash flow from operating activities was ¥3,631,925,330.95, showing a recovery from a negative cash flow of ¥3,141,561.96 in the same period last year[6] - Cash inflow from operating activities in Q1 2022 was ¥4,867,104,534.58, compared to ¥218,933,243.40 in Q1 2021, showing a growth of approximately 2,126%[26] - The net cash flow from operating activities was approximately $3.63 billion, a significant increase compared to a net outflow of approximately $3.14 million in the previous period[27] - The total cash outflow from operating activities was approximately $1.24 billion, reflecting increased operational expenses[27] - The company reported cash and cash equivalents of ¥1,907,634,230.41, down from ¥2,047,209,377.52, indicating a decrease of about 7%[16] - The cash and cash equivalents at the end of the period amounted to approximately $1.91 billion, down from $2.05 billion at the beginning of the period[28] Shareholder Information - The company reported a total of 4,296 common shareholders at the end of the reporting period[11] - The largest shareholder, Hangzhou Aixiang Holdings Co., Ltd., held 16,481,800 shares, representing 26.87% of the total shares[11] Research and Development - Research and development (R&D) expenses totaled ¥555,198,928.03, accounting for 10.14% of operating revenue, an increase of 6.62 percentage points year-over-year[6] - Research and development expenses for Q1 2022 were ¥555,198,928.03, significantly higher than ¥6,732,736.60 in Q1 2021, indicating a growth of approximately 8,247%[22] Market Performance - The increase in revenue and profit was primarily driven by the expanded market sales of COVID-19 products[9] - The significant increase in total assets and liabilities suggests potential expansion or investment activities in the upcoming quarters[17] Inventory and Receivables Management - Accounts receivable increased to ¥1,164,453,027.25 from ¥514,297,261.10, representing a growth of about 126% year-over-year[17] - Inventory rose to ¥462,494,407.76, up from ¥243,346,196.18, reflecting an increase of approximately 90%[17] - The company is actively managing its receivables and inventory levels to support future growth strategies[17] Other Financial Activities - The company reported a total cash outflow of approximately $2.48 million from financing activities, indicating no cash inflow from financing sources during the period[27] - The company did not report any cash inflow from new borrowings or investments during the period[27] - Tax payments amounted to approximately $55.56 million, a decrease from approximately $74.99 million in the previous period[27] - The impact of exchange rate fluctuations on cash and cash equivalents was a decrease of approximately $6.62 million[28]